blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2989110

EP2989110 - TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.06.2019
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  06.07.2018
FormerGrant of patent is intended
Status updated on  02.04.2018
FormerRequest for examination was made
Status updated on  10.03.2018
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Smart Brain s.r.o.
Vídenská 1083
142 20 Praha 4 / CZ
For all designated states
Biotechnologicky ustav AV CR, v.v.i.
Prumyslova 595
252 50 Vestec / CZ
For all designated states
Neuzil, Jirí
Poljanovova 3158/5
14300 Praha 4 / CZ
For all designated states
Springtide Ventures s.r.o.
Vinohradska 1511/230
100 00 Praha 10 - Strasnice / CZ
[2019/07]
Former [2018/31]For all designated states
Smart Brain s.r.o.
Vídenská 1083
142 20 Praha 4 / CZ
For all designated states
Biotechnologicky ustav AV CR, v.v.i.
Prumyslova 595
252 50 Vestec / CZ
For all designated states
Neuzil, Jirí
Poljanovova 3158/5
14300 Praha 4 / CZ
For all designated states
KKCG AG
Kapellgasse 21
6004 Luzern / CH
Former [2016/43]For all designated states
Smart Brain S.r.o.
Vídenská 1083
14220 Praha 4 / CZ
For all designated states
Biotechnologicky Ustav AV CR, v.v.i.
Videnska 1083
14220 Praha 4 / CZ
For all designated states
Neuzil, Jirí
Poljanovova 3158/5
14300 Praha 4 / CZ
For all designated states
KKCG AG
Kapellgasse 21
6004 Luzern / CH
Former [2016/21]For all designated states
Smart Brain S.r.o.
Vídenská 1083
14220 Praha 4 / CZ
For all designated states
Biotechnologicky Ustav AV CR, v.v.i.
Videnska 1083
14220 Praha 4 / CZ
For all designated states
Neuzil, Jirí
Poljanovova 3158/5
14300 Praha 4 / CZ
For all designated states
KKCG PLC
8 Alasias Street
3095 Limassol / CY
Former [2016/09]For all designated states
Smart Brain S.r.o.
Vídenská 1083
14220 Praha 4 / CZ
For all designated states
Biotechnologicky Ustav AV CR, v.v.i.
Videnska 1083
14220 Praha 4 / CZ
For all designated states
Neuzil, Jirí
Poljanovova 3158/5
14300 Praha 4 / CZ
For all designated states
KKCG SE
8 Alasias Street
Christodoulides Building
3095 Limassol / CY
Inventor(s)01 / NEUZIL, Jirí
Poljanovova 3158/5
14300 Praha 4 / CZ
02 / STURSA, Jan
Petýrkova 1948
14800 Praha4 / CZ
03 / WERNER, Lukás
Chomutovská 1229
43201 Kadan / CZ
 [2016/09]
Representative(s)Kratochvil, Vaclav
Patent and Trademark Office
P.O. Box 26
295 01 Mnichovo Hradiste / CZ
[2016/09]
Application number, filing date14721738.407.04.2014
[2016/09]
WO2014CZ00035
Priority number, dateCZ2013000030824.04.2013         Original published format: CZ 20130308
CZ2014000006629.01.2014         Original published format: CZ 20140066
[2016/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014173374
Date:30.10.2014
Language:EN
[2014/44]
Type: A1 Application with search report 
No.:EP2989110
Date:02.03.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 30.10.2014 takes the place of the publication of the European patent application.
[2016/09]
Type: B1 Patent specification 
No.:EP2989110
Date:08.08.2018
Language:EN
[2018/32]
Search report(s)International search report - published on:EP30.10.2014
ClassificationIPC:C07F9/54, A61P35/04, A61K31/662
[2016/09]
CPC:
C07F9/5456 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P35/04 (EP); A61P43/00 (EP); C07F9/5442 (EP,US);
C07F9/5449 (EP,US); C09B23/0008 (EP,US); C09B23/0025 (EP,US);
C09B23/141 (EP,US); C09B69/001 (EP,US); C09B69/008 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/09]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:TAMOXIFENDERIVATE ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN, INSBESONDERE MIT HOHEM HER2-PROTEIN-SPIEGEL[2016/09]
English:TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL[2016/09]
French:DÉRIVÉS DE TAMOXIFÈNE DANS LE TRAITEMENT DE MALADIES NÉOPLASIQUES, SPÉCIALEMENT AVEC UNE TENEUR ÉLEVÉE EN PROTÉINE HER2[2016/09]
Entry into regional phase30.10.2015National basic fee paid 
30.10.2015Designation fee(s) paid 
30.10.2015Examination fee paid 
Examination procedure30.10.2015Examination requested  [2016/09]
01.02.2016Amendment by applicant (claims and/or description)
03.04.2018Communication of intention to grant the patent
23.06.2018Fee for grant paid
23.06.2018Fee for publishing/printing paid
23.06.2018Receipt of the translation of the claim(s)
Opposition(s)09.05.2019No opposition filed within time limit [2019/29]
Fees paidRenewal fee
31.03.2016Renewal fee patent year 03
12.04.2017Renewal fee patent year 04
03.04.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL08.08.2018
CZ08.08.2018
EE08.08.2018
LT08.08.2018
LV08.08.2018
MK08.08.2018
RS08.08.2018
SM08.08.2018
[2022/31]
Former [2019/37]AL08.08.2018
CZ08.08.2018
EE08.08.2018
LT08.08.2018
LV08.08.2018
RS08.08.2018
SM08.08.2018
Former [2019/30]AL08.08.2018
CZ08.08.2018
LT08.08.2018
LV08.08.2018
RS08.08.2018
SM08.08.2018
Former [2019/26]AL08.08.2018
CZ08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
RS08.08.2018
SM08.08.2018
Former [2019/22]AL08.08.2018
CZ08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
RS08.08.2018
Former [2019/13]AL08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
RS08.08.2018
Former [2019/11]LT08.08.2018
NL08.08.2018
RS08.08.2018
Former [2019/07]LT08.08.2018
NL08.08.2018
Former [2019/04]NL08.08.2018
Cited inInternational search[A]WO9206068  (UNIV TEXAS [US]) [A] 1-14 * the whole document *;
 [YD]  - MOREIRA PI ET AL., "Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure", J BIOL CHEM, (2006), vol. 281, pages 10143 - 10152, XP002726681 [YD] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1074/JBC.M510249200
 [Y]  - SMITH R A J ET AL, "DELIVERY OF BIOACTIVE MOLECULES TO MITOCHONDRIA IN VIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20030429), vol. 100, no. 9, doi:10.1073/PNAS.0931245100, ISSN 0027-8424, pages 5407 - 5412, XP008043692 [Y] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.0931245100
by applicant   - HANAHAN D; WEINBERG RA, "Hallmarks of cancer: the next generation", CELL, (2011), vol. 1.44, pages 646 - 674
    - JONES S ET AL., "Core signalling pathways in human pancreatic cancers revealed by global genomic analyses", SCIENCE, (2008), vol. 321, doi:doi:10.1126/science.1164368, pages 1801 - 1806, XP055015968

DOI:   http://dx.doi.org/10.1126/science.1164368
    - PARSONS DW ET AL., "An integrated genomic analysis of human glioblastoma multiforme", SCIENCE, (2008), vol. 321, doi:doi:10.1126/science.1164382, pages 1807 - 1812, XP002555012

DOI:   http://dx.doi.org/10.1126/science.1164382
    - GERLINGER M ET AL., "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing", N ENGL J MED, (2012), vol. 366, doi:doi:10.1056/NEJMoa1113205, pages 883 - 892, XP055078239

DOI:   http://dx.doi.org/10.1056/NEJMoa1113205
    - RALPH SJ ET AL., "The causes of cancer revisited: ''mitochondrial malignancy'' and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy", MOL ASPECTS MED, (2010), vol. 31, pages 145 - 170, XP026995982
    - NEUZIL J ET AL., "Molecular mechanism of 'mitocan'-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins", FEBS LETT, (2008), vol. 580, doi:doi:10.1016/j.febslet.2006.05.072, pages 5125 - 5129, XP028061380

DOI:   http://dx.doi.org/10.1016/j.febslet.2006.05.072
    - NEUZIL J ET AL., "Classification of mitocans, anti-cancer drugs acting on mitochondria", MITOCHONDRION, (2013), vol. 13, doi:doi:10.1016/j.mito.2012.07.112, pages 199 - 208, XP028529914

DOI:   http://dx.doi.org/10.1016/j.mito.2012.07.112
    - ARTEAGA CL ET AL., "Treatment of HER2-positive breast cancer: current status and future perspectives", NAT REV CLIN ONCOL., (2011), vol. 9, pages 16 - 32
    - MOREIRA PI ET AL., "Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure", J BIOL CHEM, (2006), vol. 281, doi:doi:10.1074/JBC.M510249200, pages 10143 - 10152, XP002726681

DOI:   http://dx.doi.org/10.1074/JBC.M510249200
    - EWER MS; EWER SM, "Cardiotoxicity of anticancer treatments: what the cardiologist needs to know", NAT REV CARDIOL, (2010), vol. 7, doi:doi:10.1038/nrcardio.2010.121, pages 564 - 575, XP009157868

DOI:   http://dx.doi.org/10.1038/nrcardio.2010.121
    - LIN SX ET AL., "Molecular therapy of breast cancer: progress and future directions", NAT REV ENDOCRINOL, (2010), vol. 6, pages 485 - 493
    - AHN ER ET AL., "Is the improved efficacy of trastuzumab and lapatinib combination worth the added toxicity?", BREAST CANCER, (2012), vol. 6, pages 191 - 207
    - WETTERSKOG D ET AL., "Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers", ONCOGENE, (2013), pages 1 - 11
    - DONG LF ET AL., "a-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex 11", ONCOGENE, (2008), vol. 27, doi:doi:10.1038/onc.2008.69, pages 4324 - 4335, XP002533115

DOI:   http://dx.doi.org/10.1038/onc.2008.69
    - DONG LF ET AL., "Suppression of tumour growth in vivo by the mitocan a-tocopheryl succinate requires respiratory complex 11", CLIN CANCER RES, (2009), vol. 15, pages 1593 - 1600
    - DONG LF ET AL., "Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II", J BIOL CHEM, (2011), vol. 286, doi:doi:10.1074/jbc.M110.186643, pages 3717 - 3728, XP055447239

DOI:   http://dx.doi.org/10.1074/jbc.M110.186643
    - DONG LF ET AL., "Mitochondrial targeting of a-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm of efficient anti-cancer therapy", FREE RADIC BIOL MED, (2011), vol. 50, pages 1546 - 1555
    - ROHLENA J ET AL., "Mitochondrially targeted a-tocopheryl succinate is antiangiogenic: Potential benefit against tumour angiogenesis but caution against wound healing", ANTIOX REDOX SIGNAL, (2011), vol. 15, pages 2923 - 2935
    - PIERRE E. TESSIER; ANDREA J. PENWELL; FABIO E. S. SOUZA; ALEX G. FALLIS, ORGANIC LETTERS, (2003), vol. 5, no. 17, pages 2989 - 2992
    - TETRAHEDRON LETTERS, (2010), vol. 51, no. 49, pages 6426 - 6428
    - GUY CT ET AL., "Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease", PROC NATL ACAD SCI USA, (1992), vol. 89, pages 10578 - 10582
    - KLUCKOVA K ET AL., "Mitochondrial complex , a novel intriguing target for anti-cancer agents", BIOCHIM BIOPHYS ACTA, (2013), vol. 1827, pages 552 - 564
    - DING Y ET AL., "Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism", NAT COMMUN, (2012), vol. 3, page 1271
    - YANG HY; SHAO R; HUNG MC; LEE MH, "p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis", ONCOGENE, (2001), vol. 20, pages 3695 - 3702
    - HANAHAN D; WEINBERG RA, "The hallmarks of cancer", CELL, (2000), vol. 100, pages 57 - 70, XP055447752
    - THOMAS C; GUSTAFFSON J, "The different roles of ER subtypes in cancer biology and therapy", NAT REV CANCER, (2011), vol. 11, doi:doi:10.1038/nrc3093, pages 597 - 608, XP055248446

DOI:   http://dx.doi.org/10.1038/nrc3093
    - DEBLOIS D; GIGUERE V, "Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond", NAT REV CANCER, (2013), vol. 13, pages 27 - 36
    - STINGL J; CALDAS C, "Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis", NAT REV CANCER, (2007), vol. 7, pages 791 - 799
    - DESANTIS C ET AL., "Breast cancer statistics", CA CANCER J CLIN, (2011), vol. 1, pages 409 - 4018
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.